Health and Human Services Secretary Robert F. Kennedy Jr. and Food and Drug Administration (FDA) Commissioner Marty Makary ...
The FDA said it proposed significant changes to simplify biosimilarity studies and reduce what it described as unnecessary ...
President Donald Trump’s top health advisers announced a push to cut health costs by bringing more cutting-edge generic drugs ...
The FDA has revealed a set of measures designed to increase the availability of biosimilars in the U.S. and in turn reduce ...
The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may ...
The Food and Drug Administration (FDA) is launching an effort to streamline the approval process for cheaper alternative “biosimilar” versions of biologic drugs as a way to curb health costs. The ...
Generic versions of biologic drugs could hit the market without human trials and allow the market forces to bring down costs, ...
Senators cite study showing 22 times higher serious side effects from chemical abortion drugs than FDA labels indicate, ...
The U.S. Food and Drug Administration is preparing to accelerate approvals for biosimilars, or generic versions of complex ...
Health and Human Services Secretary Robert F. Kennedy Jr., and Food and Drug Administraiton (FDA) Commissioner Marty Makary are holding a press conference to speak about the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback